This completely novel finding was complemented by proof of concept studies demonstrating TMZ and PARP inhibitor pretreatment increased immune cell-mediated cytotoxicity in cells derived from a GBM PDX, which had not been previously demonstrated. This evidence concerns the gene PARP1 and glioblastoma.